Optimum News

PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.

Madrid, January 27th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist Clinical Research Organization (CRO) have today announced the launch of an Expanded Access Program (EAP) for lurbinectedin to … Continue reading “PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.”

By Optimum

PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.

Madrid, January 27th, 2020.- PharmaMar (PHM:MSE) and Bionical Emas, a global specialist Clinical Research Organization (CRO) have today announced the launch of an Expanded Access Program (EAP) for lurbinectedin to … Continue reading “PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.”

By Optimum

European CNS specialist Neuraxpharm strengthens expansion into Austrian market with acquisition of easypharm

  Acquisition of Consumer Healthcare company Easypharm OTC GmbH strengthens position in Consumer Healthcare Portfolio includes leading brands easysleep® and easyrelax®  January 23, 2020 Neuraxpharm Group (Neuraxpharm), a leading European … Continue reading “European CNS specialist Neuraxpharm strengthens expansion into Austrian market with acquisition of easypharm”

By Optimum

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function Clinically relevant secondary endpoints met, including progressive and statistically significant improvements in quality … Continue reading “Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy”

By Optimum

Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy

LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday, January … Continue reading “Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy”

By Optimum

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

Key hires enhance management for next development phase 09 January 2020, Windsor, UK: Macrophage Pharma Limited (“MPL”), a biotech company focused on the discovery and development of next-generation immunomodulatory small molecules … Continue reading “Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH